SpaceMD Advances Drug Research in Low Earth Orbit with SpaceX Starfall

Redwire’s subsidiary, SpaceMD, has secured the first operational flight of SpaceX’s Starfall to advance drug research and development in microgravity. This initiative aims to enhance drug potency and quality by manufacturing them in space. Once realized, these space-manufactured drugs will be the first physical products produced beyond Earth.

SpaceMD’s efforts mark substantial progress after decades of experiments aboard the International Space Station and the shuttle. The focus is on developing treatments for conditions such as cancer and Alzheimer’s disease in low Earth orbit. SpaceX’s Starfall, first launched on June 23, employs a Falcon 9 rocket, with capabilities for Starship deployment. The spacecraft, shaped like a disk, is approximately 2.5 feet tall with a diameter of 10.2 feet and weighs about 4,600 pounds. It can carry up to 2,200 pounds of cargo, divided between an aluminum top plate and a detachable carbon-fiber heat shield.

SpaceMD’s mission is scheduled for a 2028 launch, utilizing up to 32 Pharmaceutical In-Space Laboratory units, or PIL-BOXes, to crystallize drug compounds in microgravity. This approach aims to develop improved formulations and new therapeutics. Previous PIL-BOX versions have been deployed on the ISS, and Starfall will expand SpaceMD’s research capacity in orbit, processing over 100 different drug compounds per mission, compared to 45 on the ISS.

Microgravity-based drug crystallization eliminates gravity and temperature differences, yielding larger, more orderly drug crystals. Their structure influences dissolution rate, solubility, and bioavailability, affecting how quickly and effectively active ingredients reach the bloodstream. SpaceMD partners with ExesaLibero Pharma to develop space-grown drug crystals into market-ready pharmaceuticals, ensuring clinical trials and regulatory approval. Redwire will gain royalties from space-developed drugs marketed by ExesaLibero Pharma.

New treatments derived from space-manufactured drugs could significantly impact individuals with debilitating diseases. For instance, over 2.1 million people are anticipated to receive a cancer diagnosis in 2026, with 626,140 expected to die from the disease. Additionally, 6.7 million American adults live with Alzheimer’s, a number projected to double by 2060. Treatments that reduce these figures can alleviate human suffering and healthcare costs significantly.

While space activities have sometimes been considered extraneous, the benefits of space exploration are increasingly defensible. Politicians, including Sen. Bernie Sanders, have criticized space ventures by commercial figures like Elon Musk and Jeff Bezos. However, tangible advantages from space exploration, such as advanced drug development by Redwire, showcase the potential of this new commercial space age. Mark R. Whittington, an established space policy writer, has noted these changes in his works.